27 results about "Nipah virus" patented technology

The invention provides a pseudovirus of a Nipah virus and application of the pseudovirus, and belongs to the technical field of genetic engineering. The invention provides a pseudovirus of a Nipah virus and application of the pseudovirus. The pseudovirus contains a nucleic acid fragment of a Nipah virus N gene of which the nucleotide sequence is shown as SEQ ID NO.1. The invention further provides a preparation method of the pseudovirus. The pseudovirus of the Nipah virus can be used as a ribonucleic acid standard substance of the pseudovirus of the Nipah virus, and is applied to the aspects of quantity transmission, calibration, instrument testing, evaluation and control of a testing method, quality verification, quality control, production process detection and the like of a laboratory related to Nipah virus detection. The pseudovirus of the Nipah virus, as the ribonucleic acid standard substance of the pseudovirus of the Nipah virus, has the following advantages of accurate fixed value, good uniformity, stable quantity value and traceability, and can promote the improvement of the detection capability and the technical level of a national Nipah detection laboratory.

The present invention provides neutralizing monoclonal antibodies targeting Nipah virus G protein and their uses, wherein the monoclonal antibodies can recognize Nipah virus G protein. The present invention uses NiV G protein as an antigen target, displays antigens on a ferritin nanoparticle platform to immunize mice, and screens out three monoclonal antibodies that can specifically bind to NiV G protein. Antibody epitope competition experiments found that the S1E2 and SB10 monoclonal antibodies among these three antibodies recognize new epitopes of NiV G protein that have not been reported before. In vitro neutralization experiments have demonstrated that these three antibodies have high in vitro neutralizing activity, and can neutralize both NiV-M and NiV-B strains, with the characteristics of high expression and good stability, and can be used to prepare virus detection products such as Nipah and Hendra or drugs for preventing and treating Nipah and Hendra virus diseases.

The invention discloses application of MY-1B in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The invention mainly aims at the m5C modification of a host, and further reduces the m5C modification of the host by inhibiting the methyltransferase activity of NSUN2 so as to inhibit the replication of the Nipah virus, and has a better effect. At present, most of research and development of virus drugs and vaccines are designed or modified aiming at viruses, a new thought is provided for research and development of drugs and vaccines in the future, and a new application is also provided for MY-1B.

The invention discloses a primer pair, a probe and a kit for detecting Nipah virus and Hendea virus and application of the primer pair, the probe and the kit, and belongs to the technical field of molecular biology. The invention provides a primer pair and a probe for detecting a Nipah virus and a Hendea virus in order to solve the technical problems that a method for detecting the Nipah virus and the Hendea virus in the prior art is tedious in detection process, long in time consumption and relatively high in requirements on detection personnel and equipment, and provides a primer pair and a probe for detecting the Nipah virus and the Hendea virus. The invention also provides a single probe kit and a multi-probe kit containing the primer pair and the probe. The kit provided by the invention has relatively high specificity and sensitivity on detection of the Nipah virus and the Hendea virus, and can realize rapid visual identification and detection of the Nipah virus and the Hendea virus on an epidemic disease site.

The present invention is in the field of Nipah virus (NiV) structural protein. Particularly, the invention provides structure based stabilized Nipah virus (NiV) structural protein designing and uses thereof.

The invention discloses a human expression optimized Nipah virus N gene and application thereof in preparation of Nipah pseudovirus, belongs to the technical field of biology, and constructs a segment of Nipah virus N gene sequence optimized by human cell expression codons and constructs a recombinant vector pcDNA3.1-NiV-N-opti. The recombinant vector pcDNA3.1-NiV-N-opti is used as a pseudovirus expression vector, the recombinant vector pcDNA3.1-NiV-N-opti and pseudovirus packaging plasmids are used for preparing the kit for the nipah pseudovirus, the nipah pseudovirus can be efficiently obtained, the titer of the obtained nipah pseudovirus is higher than that of the nipah pseudovirus packaged by an original sequence, and an unexpected technical effect is achieved. Besides, the Nipah pseudovirus has His, Myc and EGFP marks, the preparation effect of the pseudovirus can be visually observed, and the Nipah pseudovirus can be used for Nipah serological diagnosis, virus neutralizing antibody evaluation and the like and has a good application prospect.

This invention belongs to the field of molecular biology detection technology, specifically relating to a Nipah virus (NiV) nucleic acid detection kit combining RT-LAMP and immunochromatography, and its application. This kit combines the high sensitivity and specificity of loop-mediated isothermal amplification (LAMP) technology with the rapid and visual interpretation advantages of immunochromatographic test strips, enabling on-site, rapid, and accurate detection of NiV. The core components of this invention include: a set of specific primers designed for conserved regions of the NiV gene, an optimized RT-LAMP reaction system, and specially treated immunochromatographic test strips for detecting LAMP amplification products. This kit eliminates the need for reverse transcription of RNA virus nucleic acids and expensive thermal cycling equipment. The entire detection process is completed within 20–30 minutes, with a sensitivity of up to 300 copies / μL. This solution combines the high efficiency of RT-LAMP technology with an intuitive, equipment-free detection method, achieving truly rapid and accurate on-site diagnosis of NiV.

The invention discloses application of carfilzomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of nipah virus M protein, the carfilzomib is used for inhibiting a host proteasome path, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and the effect is good. At present, most of research and development of virus medicines and vaccines are designed or modified aiming at viruses, a new thought is provided for research and development of medicines and vaccines in the future, and a new application is also provided for Carfilzomib.

This invention provides a polynucleotide encoding the extracellular domain of the Nipah virus G protein, a recombinant human adenovirus type 5 containing the polynucleotide, and the application of the recombinant human adenovirus type 5 in the preparation of a vaccine to prevent Nipah virus disease. The vaccine provided by this invention has good immunogenicity and can effectively and rapidly stimulate humoral and cellular immune responses in BALB / c mice.

The present invention provides protective monoclonal antibodies targeting Nipah virus (NiV) G protein and their uses, wherein the monoclonal antibodies can recognize Nipah virus G protein. The present invention uses NiV G protein as an antigen target, displays antigens on a ferritin nanoparticle platform to immunize mice, and screens out two monoclonal antibodies LN1F9 and LN1D11 that can specifically bind to NiV G protein. In vitro neutralization experiments have shown that these two antibodies have high neutralizing activity against both NiV-M and NiV-B strains, among which LN1F9 can also neutralize Hendra virus (HeV) of the same genus. The monoclonal antibodies LN1F9 and LN1D11 can effectively treat hamsters infected with NiV and prevent NiV infection in hamsters. They have extremely high application value in clinical treatment and prevention of NiV and HeV infection, and can be used to prepare detection products and preventive and therapeutic drugs for NiV and HeV.

The present invention provides a Nipah virus (NiV) vaccine composition comprising (i) a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a soluble Nipah virus glycoprotein (soluble NiV-G) fused to a human type I collagen alpha 1 (COL1A1) signal peptide, (ii) an mRNA comprising an ORF encoding a full length NiV-G, and (iii) a vaccine composition comprising (i) a messenger ribonucleic acid (mRNA) encoding an ORF encoding a full length NiV-G signal peptide. (iii) an mRNA comprising an ORF encoding a full-length Nipah virus fusion protein (full-length NiV-F) or (iv) an mRNA comprising an ORF encoding a full-length NiV-G, and an mRNA comprising an ORF encoding a full-length NiV-F, and a method of inducing an immune response against Nipah virus by administering to a subject in need thereof an effective amount of a Nipah virus vaccine composition.

The present invention relates to an engineered monoclonal antibody having fragments of heavy chain (HC) and light chain (LC) selected from SEQ ID No. 1, 2, 3, 4, 5, 6, 7, 8, 9 10, 11, 12, 13, 14 and 15 or a combination thereof for interacting and neutralizing Nipah virus as well as Hendra virus isolate. The present invention also discloses the method of production of monoclonal antibodies and its use thereof.

Provided herein are (i) messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a soluble Nipah virus glycoprotein (soluble NiV-G) fused to a human type I collagen alpha 1 (COL1A1) signal peptide, (ii) an mRNA comprising an ORF encoding the full-length Nipah virus glycoprotein (full-length NiV-G), (iii) an mRNA comprising an ORF encoding the full-length Nipah virus fusion protein (full-length NiV-F), or (iv) an mRNA comprising an ORF encoding full-length NiV-G and an ORF encoding full-length NiV-F, as well as methods for inducing an immune response against Nipah virus by administering an effective amount of the Nipah virus vaccine composition to a subject in need thereof.

A portable AI-based VOC detection device, consisting of: a portable housing with a micro air intake pump for contactless air sampling, ensuring hygienic sampling; an ionization module that uses UV light to break down VOCs, and a miniature mass spectrometer for the analysis of molecular fragments; a machine learning model trained to detect Nipah virus-specific VOC signatures and to identify unknown or emerging disease patterns in order to warn users of potential health risks; a detection indicator system with LED display and acoustic alarm system for real-time notifications of detection results; and a wireless communication and power supply system with WLAN connectivity for AI model updates, as well as a rechargeable lithium-ion battery for low power consumption and high efficiency.

The application discloses a PCR chip for monitoring Nipah virus and products and applications thereof, and relates to the technical field of biological detection. The application provides a PCR chip for monitoring Nipah virus, which comprises the following primers and probes: primers and probes for detecting Nipah virus M subtype; and primers and probes for detecting Nipah virus B subtype. The kit has excellent detection capability for Nipah virus M subtype, Nipah virus B subtype and Hendra virus, is high in sensitivity, good in specificity, accurate and reliable in detection result, strong in repeatability, simple in operation and short in time consumption. The kit can simultaneously realize the differentiation of Nipah virus M / B subtypes and the identification of Hendra virus in a single sample, and provides technical support for the rapid identification of Nipah virus and Hendra virus.

The present invention provides a pseudotyped retroviral vector particle comprising a) one envelope protein with antigen-binding activity (protein H of a CDV or protein G of a Nipah virus) fused at its ectodomain to a polypeptide that specifically binds to CD4 and / or CD8, and b) one envelope protein with fusion activity (protein F of the virus as the protein H / G), and c) a nucleic acid molecule encoding a transgene, wherein said transgene is a chimeric antigen receptor (CAR) comprising an antigen-specific targeting region, at least one transmembrane domain, and at least one intracellular signaling domain, wherein said antigen-specific targeting region comprises a first antigen binding domain, specific for a first antigen expressed on the surface of a disease-associated target cell and a second antigen binding domain specific for a second antigen expressed on the surface of said disease-associated target cell, and wherein said retroviral vector particle is a lentiviral or gammaretroviral vector particle. Preferentially said antigen binding domains of the CAR are of human origin, more preferentially the CAR has specificity for CD20 and CD19.

The application provides a kit for detecting nipah virus antigen and application thereof, and belongs to the technical field of biotechnology.The kit comprises quantum dot microsphere labeled nipah virus N protein specific antibody, quantum dot microsphere labeled nipah virus G protein specific antibody, loading liquid and detection test paper.The kit can set double detection lines for nipah virus N protein and G protein on the same detection test paper, realize synchronous combined detection of double targets, avoid false negative and missed detection risk caused by antigen expression abundance difference in different infection stages of viruses, different expression time and improper sampling time in single target detection mode, and significantly improve the overall detection rate of samples.The kit is simple in operation, rapid in detection, does not need large and precise instruments, can realize on-site and real-time qualitative and quantitative detection of samples, is suitable for large-scale rapid screening in primary field and epidemic area, and has good practical application value and popularization prospect.

The invention provides a high-throughput screening method of an anti-Nipah virus drug. The method comprises the following steps: firstly, completing drug gradient dilution and planking pretreatment in a BSL-2 laboratory; then carrying out virus infection, cell culture and 72-hour incubation in the BSL-4 core region; the method comprises the following steps: carrying out rapid and low-cost visual preliminary screening on a whole-plate sample through crystal violet dyeing, and selectively carrying out TRIzol LS inactivation treatment on a small amount of potential effective sample supernatant; after the inactivated sample is transferred to a BSL-2 laboratory, the virus copy number is accurately quantified by adopting a qRT-PCR technology, and finally the drug inhibition ratio and the EC50 value are calculated. According to the method, through a staged screening strategy, on the premise of ensuring biological safety, the screening flux is greatly improved, the detection cost is reduced, and a reliable solution is provided for drug screening of high-pathogenicity pathogenic microorganisms.

The invention provides a specific envelope protein as well as a lentiviral vector and application thereof. The specific envelope protein comprises F protein Nipah-F of a Nipah virus, an antibody and G protein modified protein derived from the Nipah virus. The envelope protein derived from the Nipah virus is modified, so that the envelope protein retains the membrane melting capability and obtains the specific targeting capability of cells. The method is characterized in that targeting proteins with a ligand recognition function, such as a single-chain antibody scFv, an ankyrin repeat protein DARPin and the like, are fused with a G protein modified protein derived from the Nipah virus, and are connected with a Nipah-F protein. The specific envelope protein is used for packaging lentivirus, retrovirus vectors, viroid and other vectors, so that the vectors specifically recognize antigens on cell membranes, and cell targeting nucleic acid delivery is completed. According to the invention, T cells can be modified in vivo, and genetically modified T cells can be generated in vivo, so that procedures related to return CAR-T cell therapy are greatly reduced.

The invention relates to a Nipah virus and Hendea virus double-antigen vaccine based on a chimpanzee adenovirus vector and application of the Nipah virus and Hendea virus double-antigen vaccine. The double-antigen vaccine is obtained by directionally cloning a human CMV (cytomegalovirus) promoter, codon optimization sequences for coding NiV fusion glycoprotein (F) (NiV F) and HeV attachment glycoprotein (G) (HeV G) and an expression cassette of SV40 to an E1 deletion site of a chimpanzee adenovirus vector, constructing recombinant plasmids, and packaging and processing the recombinant plasmids. According to the present invention, the replication-deficient chimpanzee adenovirus vector is utilized to express the NiV F protein and the HeV G protein, the vaccine aiming at the two viruses is developed, the effect of preventing two diseases through one injection is achieved, and compared with the single-antigen vaccine in the prior art, the double-antigen vaccine of the present invention has great advantages in practicality and economy.

The application discloses application of STM2457 in preparation of medicines for preventing and treating nipah virus, and belongs to the technical field of medicines.The application mainly aims at m6A modification of a host, inhibits methyltransferase activity of METTL3 through STM2457, and then reduces m6A modification of the host to inhibit replication of the nipah virus, and has good effect.At present, most of the researches on virus medicines and vaccines are designed or modified according to the virus itself, the application provides a new idea for future drug research and development and vaccine research, and also provides a new use for STM2457.

The invention discloses application of ixazomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of the nipah virus M protein, the host proteasome pathway is inhibited through the ixazomib, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and a good effect is achieved. The ixazomib is used as a nipah virus inhibitor, belongs to a new application of an old medicine, and provides a new application for the ixazomib. And the safety of the ixazomib has no problem, so that the ixazomib can be applied clinically. In addition, at present, most of research and development of virus drugs and vaccine research are designed or modified aiming at viruses, and a new thought is provided for research and development of drugs and vaccines in the future.

The invention provides a monoclonal antibody combination for Nipah virus detection, an AlphaLISA detection method of Nipah virus and a colloidal gold immunochromatography detection method of Nipah virus, and belongs to the technical field of virus detection. According to the invention, hundreds of antigen-specific B cells are separated from immunized mice, and five stably secreted mAbs are obtained. All antibody heavy chains and light chains can specifically recognize the Nipah virus G protein. The detection limit of the AlphaLISA detection method of the NiV-22 / NiV-12 antibody combination is as low as 0.024 ng / mL, which is about 100 times higher than that of the traditional ELISA, and no cross reaction exists in the test of five heterologous virus antigens. The sensitivity of the colloidal gold immunochromatography detection method of the NiV-22 / NiV-12 antibody combination to G protein reaches 1 ng / mL, the detection sensitivity to Nipah virus pseudovirus reaches 945 TU / mL, and no cross reaction exists in the test of five heterologous virus antigens.

The invention relates to an application of Remodelin in preparation of an anti-Nipah virus drug. The Remodelin can inhibit budding of NiV particles and prevent the virus from being copied in host cells; and the Remodelin can inhibit the duplication of NiV and reduce the virus copy number after NiV infection, and can be used as an NiV inhibitor for preventing or treating NVD.

The application discloses application of MY-1B in preparation of medicines for preventing and treating nipah virus, and belongs to the technical field of medicines.The application is mainly directed to m5C modification of a host, and the methyltransferase activity of NSUN2 is inhibited, so that the m5C modification of the host is reduced, and the replication of the nipah virus is inhibited, and good effects are achieved.At present, most of the researches on virus medicines and vaccines are designed or modified according to the virus itself, and the application provides a new idea for future medicine research and development and vaccine research, and also provides a new use for MY-1B.

This invention provides a monoclonal antibody combination for Nipah virus detection, along with an AlphaLISA and colloidal gold immunochromatographic assay for Nipah virus detection, belonging to the field of virus detection technology. This invention isolates hundreds of antigen-specific B cells from immunized mice, obtaining five stably secreted mAbs. All antibody heavy and light chains specifically recognize the Nipah virus G protein. The AlphaLISA assay using the NiV-22 / NiV-12 antibody combination has a detection limit as low as 0.024 ng / mL, approximately 100 times lower than traditional ELISA, and shows no cross-reactivity in the tests of five heterologous viral antigens. The colloidal gold immunochromatographic assay using the NiV-22 / NiV-12 antibody combination achieves a sensitivity of 1 ng / mL for G protein detection and a sensitivity of 945 TU / mL for Nipah virus pseudovirus detection, showing no cross-reactivity in the tests of five heterologous viral antigens.

This invention belongs to the field of virology, specifically relating to a chimeric VSV recombinant virus and its applications; specifically, it discloses a chimeric VSV recombinant virus strain co-expressing NiV G and F proteins, wherein the chimeric VSV recombinant virus strain is rVSV△G / NiVMYGF and rVSV△G / NiVBDGF; based on its complete viral structure, higher immunogenicity and better safety, it can serve as an important viral reserve resource for the effective prevention and control, diagnosis and detection, vaccine preparation and antiviral treatment products of Nipah disease in the future.